X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration will initially focus on developing an at home self-administered subcutaneous version of a lead oncology asset, and up to four additional targets using Elektrofi's innovative formulation technology platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: JANSSEN BIOTECH
Deal Size: $793.0 million Upfront Cash: $18.0 million
Deal Type: Collaboration January 03, 2024
Details:
The agreement aims to develop next-generation medicines that can be delivered subcutaneously by using Elektrofi’s ultra-high concentration microparticle suspension technology platform.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $470.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement October 24, 2023
Details:
Under the terms of this collaboration and license agreement, Argenx and Elektrofi will explore new subcutaneous formulations for therapeutic products directed at the human neonatal Fc receptor (FcRn), including efgartigimod, and up to one additional target.
Lead Product(s): Efgartigimod
Therapeutic Area: Immunology Product Name: ARGX-113
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Argenx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
